Sagent Pharmaceuticals Inc (SGNT) financial statements (2022 and earlier)

Company profile

Business Address 1901 NORTH ROSELLE ROAD, SUITE 700
SCHAUMBURG, IL 60195
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments36334946716974
Cash and cash equivalents16132926514956
Short-term investments20202020202018
Receivables53535446475645
Inventory, net of allowances, customer advances and progress billings87837676726262
Inventory87837676726262
Disposal group, including discontinued operation  5    
Other undisclosed current assets109718171918
Total current assets:185177192186206206199
Noncurrent Assets
Property, plant and equipment28242068707071
Long-term investments and receivables8876655
Long-term investments8876655
Intangible assets, net (including goodwill)84847883878594
Goodwill27272525272628
Intangible assets, net (excluding goodwill)58575358605966
Other noncurrent assets1122000
Other undisclosed noncurrent assets52525114141313
Total noncurrent assets:174169158174177174183
TOTAL ASSETS:359346350360384379381
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities64565958647162
Accounts payable49424436444733
Accrued liabilities15141615131619
Employee-related liabilities   5579
Taxes payable   1111
Debt   0001
Due to related parties1614141210118
Disposal group, including discontinued operation  3    
Other undisclosed current liabilities6681131115
Total current liabilities:86768471869386
Noncurrent Liabilities
Long-term debt and lease obligation6322222
Long-term debt, excluding current maturities6322222
Liabilities, other than long-term debt13141315161618
Deferred tax liabilities, net12121212141416
Other liabilities1112223
Total noncurrent liabilities:19161516181820
Total liabilities:105939987104111106
Stockholders' equity
Stockholders' equity attributable to parent254253251273279268276
Common stock0000000
Additional paid in capital369368367365363354353
Accumulated other comprehensive loss(11)(11)(17)(15)(8)(10)(3)
Accumulated deficit(104)(104)(99)(78)(76)(76)(74)
Total stockholders' equity:254253251273279268276
TOTAL LIABILITIES AND EQUITY:359346350360384379381

Income statement (P&L) ($ in millions)

6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
Revenues
(Revenue, Net)
72688375778384
Cost of revenue
(Cost of Goods and Services Sold)
(54)(51)(60)(51)(59)(61)(59)
Gross profit:17172324182224
Operating expenses(20)(20)(25)(20)(17)(22)(19)
Other undisclosed operating income (loss)2(4)(45)(2)   
Operating income (loss):(0)(7)(47)21(0)5
Nonoperating income (expense)01(1)(2)1(1)(0)
Investment income, nonoperating (6)     
Interest and debt expense(0)(0)(0)(0)(0)(0)(2)
Income (loss) from continuing operations before equity method investments, income taxes:(1)(6)(48)(0)2(2)3
Income (loss) from equity method investments  (2)0012
Other undisclosed income (loss) from continuing operations before income taxes  2(0)(0)(1)(2)
Income (loss) from continuing operations before income taxes:(1)(6)(48)(0)2(2)3
Income tax expense (benefit)0130(2)(2)(0)26
Net income (loss) available to common stockholders, diluted:(1)(5)(18)(2)(0)(2)30

Comprehensive Income ($ in millions)

6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
Net income (loss):(1)(5)(18)(2)(0)(2)30
Other comprehensive income (loss)(0)6     
Other undisclosed comprehensive loss  (14)   (4)
Comprehensive income (loss):(1)1(32)(2)(0)(2)26
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  11(7)2(7)0
Comprehensive income (loss), net of tax, attributable to parent:(1)1(21)(8)2(9)26

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: